Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 5Terminated 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Plasma cell 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Metastatic Castrate Resistant Prostate Cancer 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × tasquinimod × Clear all
NCT04405167 2025-10-07

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

University of Pennsylvania

Phase 1 Terminated
30 enrolled
Plasma cell

Multiple Myeloma

NCT02057666 2021-04-23

TasQ003

Ipsen

Phase 3 Terminated
146 enrolled 13 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT01732549 2019-11-22

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Ipsen

Phase 2 Terminated
144 enrolled 22 charts
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡